Total gross proceeds of up to $150.0 million before the end of 2026 if all Series B warrants and Series C warrants are ...

Later this month, the Food and Drug Administration is widely expected to approve a groundbreaking twice-yearly injection to ...

Gilead Sciences Inc. closed 7.92% below its 52-week high of $119.96, which the company achieved on March 10th.

Gilead's HIV drug lenacapavir earns FDA priority review after strong trial results, with the company planning to double U.S.

Jefferies analyst Michael Yee reaffirmed a Buy rating on Gilead Sciences Inc. (NASDAQ:GILD), maintaining his price target at ...

Impax Asset Management, an investment management company, released its “Impax US Sustainable Economy Fund” first quarter 2025 ...

Hulu’s television adaptation of Margaret Atwood’s landmark 1985 feminist novel, The Handmaid’s Tale, has now come to an end.

J&J has a multi-year head start, but Gilead believes it can win market share by delivering a drug with better safety and at ...

Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, ...

The series had introduced Elisabeth Moss as June, a mother and wife who was captured by the totalitarian fascist regime the ...

Shares of Gilead Sciences Inc. GILD slid 1.06% to $108.91 Monday, on what proved to be an all-around favorable trading ...

"The Handmaid's Tale" comes to an end after six seasons on Hulu. One of the stars, O-T Fagbenle, talks about his character and the show's cultural impact.